T&R Biofab , Ltd. EBIT

T&R Biofab , Ltd.'s ebit stands at $-7.1B as of June 2026. That compares with $-7.3B in the prior-year period — up 2.5% year over year. That is below the sector sector average of $2.6T. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

T&R Biofab , Ltd. reported $-7.1B in EBIT versus $-7.3B a year earlier — a 2.5% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

T&R Biofab , Ltd. sits lower the its sector benchmark ($2.6T) with a EBIT of $-7.1B. That is roughly 100.3% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $-7.3B in the prior-year period — up 2.5% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how T&R Biofab , Ltd.'s EBIT evolved across reporting periods, while the comparison chart places 246710.KQ next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.